Vitiligo News

Healio has compiled March’s most-read news in dermatology.

Incyte has entered into a collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib, the companies announced in a press release.

SAN DIEGO — Patients with nonsegmental vitiligo continually improved with upadacitinib treatment up to 1 year, according to a speaker at the American Academy of Dermatology Annual Meeting.

SAN DIEGO — In patients with active nonsegmental vitiligo, ritlecitinib monotherapy or paired with twice weekly narrowband ultraviolet B phototherapy improved facial and total body repigmentation, according to a speaker here.

Topical ruxolitinib cream significantly reduced skin manifestations caused by cutaneous graft-versus-host disease compared with vehicle cream, results from a randomized phase 2 study showed.

MIAMI BEACH, Fla. — Janus kinase inhibitors have a unique mechanism of action, giving them the potential to push the boundaries of efficacy in the treatment of inflammatory skin diseases, according to a speaker at South Beach Symposium.

In addition to cutting edge content, the 22nd annual South Beach Symposium has added a “unique session” that focuses on how the medical and cosmetic dermatologist can work together to holistically treat patients.

VYN201 showed positive effects on biomarkers of vitiligo in a phase 1b trial, VYNE Therapeutics announced in a press release.

In this edition, dermatologists ‘uniquely positioned’ to aid human trafficking victims; FDA approves Cosentyx for hidradenitis suppurativa and more.

CHICAGO — An autologous skin cell suspension device allows for faster, more accessible and efficacious melanocyte-keratinocyte transplant procedures for vitiligo, according to a presentation here.